PSP94 diagnostic reagents and assays
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jan 15, 2004
app pub date -
May 1, 2003
filing date -
May 1, 2002
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
In the serum, PSP94 occurs as a free form or is associated with a carrier protein. PSP94 in its bound form has been quantified in the blood of prostate cancer patients and these measurements have shown utility as evaluation of prognosis. The present invention identifies a carrier protein to which PSP94 is bound (named PSP94-binding protein) its purification process, its nucleic acid and amino acid sequence and to the use of these sequences in the diagnosis and prognosis of PSP94 related disease. More particularly, the present invention discloses improved diagnostic and prognostic assays as well as reagents useful for the evaluation of conditions linked with abnormal or elevated levels of PSP94, such as prostate cancer and benign prostatic hyperplasia.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully